Market Research Logo

Chemotherapy Induced Anemia - Pipeline Review, H2 2016

Chemotherapy Induced Anemia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Anemia - Pipeline Review, H2 2016’, provides an overview of the Chemotherapy Induced Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
    • The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects
    • The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Chemotherapy Induced Anemia Overview
    Therapeutics Development
    Pipeline Products for Chemotherapy Induced Anemia - Overview
    Chemotherapy Induced Anemia - Therapeutics under Development by Companies
    Chemotherapy Induced Anemia - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Chemotherapy Induced Anemia - Products under Development by Companies
    Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
    3SBio Inc.
    BIOCAD
    Chong Kun Dang Pharmaceutical Corp.
    Dr. Reddy's Laboratories Limited
    Galenica Ltd.
    Panacea Biotec Limited
    Pfizer Inc.
    PharmaEssentia Corporation
    PhytoHealth Corporation
    Pieris Pharmaceuticals Inc
    Sandoz International GmbH
    SBI Pharmaceuticals Co., Ltd.
    Therapure Biopharma Inc.
    Tolero Pharmaceuticals, Inc.
    Chemotherapy Induced Anemia - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epoetin zeta - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ferric carboxymaltose - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-1116 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PHN-013 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRS-080 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SSS-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TBI-304H - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-0184 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-0413 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TXA-302 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chemotherapy Induced Anemia - Dormant Projects
    Chemotherapy Induced Anemia - Discontinued Products
    Chemotherapy Induced Anemia - Product Development Milestones
    Featured News & Press Releases
    Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
    Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
    Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
    Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
    Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
    Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
    Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended
    Aug 09, 2010: Dr Reddy’s Launches Darbepoetin Alfa For Treatment Of Anemia In India
    Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world’s first complex biosimilar
    Jan 07, 2008: Sandoz and Gambro form strategic alliance
    Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Chemotherapy Induced Anemia, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H2 2016
    Chemotherapy Induced Anemia - Pipeline by BIOCAD, H2 2016
    Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
    Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
    Chemotherapy Induced Anemia - Pipeline by Galenica Ltd., H2 2016
    Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H2 2016
    Chemotherapy Induced Anemia - Pipeline by Pfizer Inc., H2 2016
    Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corporation, H2 2016
    Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corporation, H2 2016
    Chemotherapy Induced Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2016
    Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H2 2016
    Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016
    Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H2 2016
    Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Chemotherapy Induced Anemia - Dormant Projects, H2 2016
    Chemotherapy Induced Anemia - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Chemotherapy Induced Anemia, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report